Related Experiment Video
Updated: Jul 15, 2026
04:50
Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain
Published on: May 16, 2025
Rheumatoid arthritis and reproduction
Amit Golding1, Uzma J Haque, Jon T Giles
1Division of Rheumatology, The Johns Hopkins University School of Medicine, Baltimore, MD 21224, USA. gilesjont@jhmi.edu
Rheumatic Diseases Clinics of North America
|May 15, 2007
Summary
Further research is required to confirm the safety of biologic agents during pregnancy and breastfeeding. Healthcare providers must educate women of childbearing age with rheumatoid arthritis about disease progression and medication risks before conception.
Area of Science:
- Rheumatology
- Obstetrics
- Pharmacology
Background:
- Rheumatoid arthritis (RA) management during pregnancy presents unique challenges.
- Limited data exists on the safety of biologic agents in pregnant and lactating individuals.
- Optimal outcomes necessitate proactive patient education.
Purpose of the Study:
- To highlight the need for further research on biologic agent safety in pregnancy and lactation.
- To emphasize the importance of comprehensive counseling for women of childbearing age with RA.
Main Methods:
- This is a review and expert opinion piece.
- It synthesizes current knowledge on RA, pregnancy, and biologic therapies.
Main Results:
- Current evidence is insufficient to definitively establish the safety profile of biologic agents during pregnancy and lactation.
- The natural history of RA during pregnancy and potential pharmacotherapy risks require thorough patient communication.
Conclusions:
- Enhanced research is crucial to ascertain the safety of biologic agents for pregnant and breastfeeding women.
- Early and thorough counseling regarding RA's course in pregnancy and medication risks is essential for women of childbearing age with RA to ensure optimal maternal and fetal outcomes.
Related Concept Videos
01:23Rheumatic Heart Disease I: Introduction
Rheumatic heart disease or RHD is a chronic condition that results from rheumatic fever, causing permanent damage to the heart valves.Etiology and Risk FactorsIt primarily arises from rheumatic fever, an inflammatory disease that can develop after untreated or inadequately treated group A streptococcal (GAS) pharyngitis. Streptococcus spreads through direct contact with oral or respiratory secretions. While the bacteria are the causative agents, factors like malnutrition, overcrowding, poor...
01:11Genome-wide Association Studies-GWAS
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
GWAS does not require the identification of the target gene involved in...
01:22Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...
01:21Rheumatic Heart Disease III: Medical Management
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
01:20The JAK-STAT Signaling Pathway
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
01:24T Cell Types and Functions
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...